Researchers at Yale University have developed a proteosome inhibitor that is released into a cell only if that cell is infected with HIV. The "Trojan Horse" has a steric, dendrimer cap that is cleaved only by HIV-1 protease, which releases the drug into the cell killing it so that the HIV cannot corrupt the cellular machinery for its own replication. The research builds on an earlier drug developed by the team to act as a cytotoxic epoxyketone proteasome inhibitor for treating cancer. That drug is currently in Phase III clinical trials. There is an obstacle to the success of the modified drug in that HIV must be active to trigger its own downfall.
Trojan beats HIV